ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.15), FiscalAI reports. ProQR Therapeutics had a negative net margin of 255.83% and a negative return on equity of 65.89%. The firm had revenue of $2.35 million for the quarter, compared to the consensus estimate of $5.19 million.
ProQR Therapeutics Trading Down 1.5%
Shares of NASDAQ PRQR traded down $0.03 during midday trading on Thursday, reaching $1.68. The company had a trading volume of 196,246 shares, compared to its average volume of 522,088. The business’s 50-day simple moving average is $1.69 and its 200 day simple moving average is $1.87. The stock has a market cap of $176.48 million, a P/E ratio of -3.64 and a beta of 0.08. ProQR Therapeutics has a 1 year low of $1.33 and a 1 year high of $3.10.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Osaic Holdings Inc. raised its holdings in shares of ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 4,500 shares during the last quarter. Guggenheim Capital LLC purchased a new stake in ProQR Therapeutics during the 4th quarter valued at about $35,000. Invesco Ltd. purchased a new stake in ProQR Therapeutics during the 4th quarter valued at about $51,000. Simplex Trading LLC grew its stake in ProQR Therapeutics by 44,169.0% during the 4th quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company’s stock valued at $89,000 after purchasing an additional 44,169 shares during the last quarter. Finally, Persistent Asset Partners Ltd grew its stake in ProQR Therapeutics by 24.5% during the 4th quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock valued at $91,000 after purchasing an additional 8,874 shares during the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Report on ProQR Therapeutics
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.
Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.
Featured Stories
- Five stocks we like better than ProQR Therapeutics
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
- The Great SPR Arbitrage: An Oil Market Glitch Fuels Sector Gains
- Why Satellogic Could Be One of the Biggest Space Winners of 2026
- Dividend Growth or High Yield: The Income Investor’s Bet
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
